Rapport Therapeutics (RAPP) Current Leases (2023 - 2026)

Rapport Therapeutics (RAPP) has reported Current Leases for 4 consecutive years, with $2.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases rose 159.42% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $2.6 million (up 159.42% YoY), while the FY2025 annual figure was $2.8 million, up 273.81% from the prior year.
• Current Leases slipped to $2.6 million in Q1 2026 per RAPP's latest filing, from $2.8 million in the prior quarter.
• Across five years, Current Leases topped out at $2.8 million in Q4 2025 and bottomed at $670000.0 in Q4 2023.
• Historically, Current Leases has averaged $1.5 million across 4 years, with a median of $1.0 million in 2025.
• Annual changes were most pronounced in 2024 — Current Leases increased 10.0% — and 2025, when it soared 273.81%.
• Rapport Therapeutics' Current Leases stood at $670000.0 in 2023, then climbed by 10.0% to $737000.0 in 2024, then jumped by 273.81% to $2.8 million in 2025, then retreated by 5.08% to $2.6 million in 2026.
• Business Quant data shows RAPP's Current Leases at $2.6 million in Q1 2026, $2.8 million in Q4 2025, and $2.5 million in Q3 2025.